Torrent Pharmaceuticals Limited
TORNTPHARM
Peringkat dalam Saham
#1210
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity,... Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
Harga Saham
$49.76
Kapitalisasi Pasar
$18.93B
Perubahan (1 hari)
-1.09%
Perubahan (1 tahun)
21.98%
Negara
IN
Perdagangan Torrent Pharmaceuticals Limited (TORNTPHARM)
Kategori
Healthcare
Rasio P/E untuk Torrent Pharmaceuticals Limited (TORNTPHARM)
Rasio P/E per October 2026 TTM: 71.64
Menurut laporan keuangan dan harga saham terbaru dari Torrent Pharmaceuticals Limited, rasio P/E saat ini (TTM) adalah 71.64. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar 54.66.
Riwayat rasio P/E untuk Torrent Pharmaceuticals Limited dari 2005 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 71.64 | 27.07% |
| 2025 | 56.38 | 3.14% |
| 2024 | 54.66 | 30.84% |
| 2023 | 41.78 | -31.28% |
| 2022 | 60.79 | 76.71% |
| 2021 | 34.40 | 5.65% |
| 2020 | 32.56 | -55.81% |
| 2019 | 73.70 | 133.20% |
| 2018 | 31.60 | 12.29% |
| 2017 | 28.14 | 113.73% |
| 2016 | 13.17 | -49.56% |
| 2015 | 26.11 | 95.38% |
| 2014 | 13.36 | 0.29% |
| 2013 | 13.32 | -29.07% |
| 2012 | 18.78 | 3.34% |
| 2011 | 18.18 | -8.93% |
| 2010 | 19.96 | 224.61% |
| 2009 | 6.15 | -30.48% |
| 2008 | 8.85 | -50.07% |
| 2007 | 17.72 | -50.96% |
| 2006 | 36.12 | 88.10% |
| 2005 | 19.21 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -51.20% |
IN
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.